Population Pharmacokinetic Model Evaluation with a Small Real-World Dataset Versus a Large Virtual Dataset: Does
Mehdi El Hassani1,2, Daniel J G Thirion3,4, Amélie Marsot3,5
1Faculté de pharmacie, Université de Montréal, 2940 chemin de Polytechnique, Montréal, QC, H3T 1J4, Canada. mehdi.el.hassani@umontreal.ca.
Background And Objective:
In a recent simulation-based study, we found that sample size had minimal influence on the external evaluation of population pharmacokinetic (PK) models. However, the applicability of these findings to clinical data remains unexplored. This study aims to validate our previous simulation-based results using real-world clinical data.
Methods:
Data from a prospective clinical study in the > 75-year-old population admitted to the McGill University Health Center (MUHC) receiving piperacillin/tazobactam were collected. A virtual population of 1000 patients representative of the characteristics of MUHC patients was also simulated. A population PK model was externally evaluated both using the small clinical dataset and a larger simulated dataset. The predictive performance of the model was assessed using bias, imprecision, goodness-of-fit plots (GOF), and prediction-corrected visual predictive checks (pcVPC). The distribution of prediction errors between the clinical and simulated datasets was compared using the Wilcoxon rank-sum test.
Results:
Data from 13 patients undergoing piperacillin/tazobactam therapy were collected. The Ishihara et al. model showed low bias (2.4% population, 0.5% individual) and imprecision (23.8% and 3.2%) and was therefore chosen for Monte Carlo simulation of the virtual population. The Hemmersbach-Miller et al. model showed bias values of - 37.8% (population) and - 21.4% (individual), with imprecision values of 43.2% (population) and 31.3% (individual) for the clinical dataset. For the simulated population, bias values were - 28.4% (population) and - 13.9% (individual), with imprecision values of 40.2% (population) and 18.1% (individual). No significant difference was observed between the prediction error distributions of the clinical and simulated datasets. Both GOF plots and pcVPCs showed similar model misspecification across the clinical and simulated datasets.
Conclusions:
This study confirms that small clinical datasets may be used to externally evaluate population PK models.
Related Concept Videos
01:12Analysis of Population Pharmacokinetic Data
01:26Pharmacokinetic Models: Comparison and Selection Criterion
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
01:06Model Approaches for Pharmacokinetic Data: Distributed Parameter Models
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
01:20Pharmacokinetic Models: Overview
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
01:14Model Approaches for Pharmacokinetic Data: Compartment Models
Two primary types of compartment models are recognized: mammillary and catenary. The more...
01:14Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...